Bernard A. Fox, Co- founder, President, and CEO of UbiVac, shared Patrick Hwu’s, President and CEO at Moffitt Cancer Center, shared OncoDaily’s post on LinkedIn, adding:
“Thank You OncoDaily for posting and highlighting our recent review on Cancer’s Dark Genome-derived non-canonical proteins, also termed cancer’s Dark Matter.
The discovery of these proteins and the role they play in cancer’s development and progression opens a spectrum of immunologic and pharmacological opportunities to finish cancer!
New developments are happening almost every week. Last week’s meeting outside Berlin combined with a landmark paper in Nature – underscored how fast this field is evolving
Merck, BioNTech, and Boehinger are playing in the space. Which pharma will be next? Dave Ricks?
UbiVac’s Dark Antigen Cancer Vaccine – the 1st in the clinic – and developed with NCI SBIR$ – contains more than 400 of these non-canonical antigens, has induced responses to Dark Matter antigens in vivo, and combined with Incyte‘s CPI has tripled response rates, tripled CR rates, and more than doubled overall survival in a phase 1b trial for HNSCC!
What else is happening in this space?
Epitopea will Launch their dark antigen trial soon, who will be the third biotech with a dark antigen immunotherapy trial? Watch for the VAXON 2026 program – Oct 5th in Napoli – and come to catch up on the latest developments in cancer vaccines. Currently looking for companies to help sponsor.
The 2025 VAXON link is here.”